Neurocysticercosis Clinical Trial
— TEPIMOfficial title:
Establishment and Application of a Taenia Solium Experimental Pig Infection Model and Investigation of Environmental Factors Associated With Transmission of T. Solium in Endemic Villages of Eastern and Southern Provinces of Zambia
NCT number | NCT03874689 |
Other study ID # | TEPIM |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | June 1, 2019 |
Est. completion date | December 31, 2022 |
Verified date | November 2023 |
Source | Technical University of Munich |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study aims to determine the prevalence of taeniosis and (neuro)cysticercosis in two districts in the southern (Gwembe) and eastern province (Chipata) of Zambia.
Status | Completed |
Enrollment | 2921 |
Est. completion date | December 31, 2022 |
Est. primary completion date | December 31, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 10 Years and older |
Eligibility | Inclusion Criteria: - Willing and able to participate in all aspects of the study, including providing blood and stool samples, participating in a questionnaire survey and group discussions, and taking oral anthelmintic tablets - Willing and able to provide informed consent (signature or thumbprint with impartial witness; assent for minors with parental consent). - Living in, attending school in, or regularly visiting the bore holes present in, the study communities. - Aged 10 years or older Exclusion Criteria: - Unwilling or unable to participate in some or all aspects of the study, including providing blood and stool samples, participating in a questionnaire survey and group discussions, or taking oral anthelmintic tablets. - Unwilling or unable to provide written (signature or thumbprint with impartial witness) informed consent (or assent for minors). - Living outside of, and not regularly visiting, or attending school in, the study communities. - Children aged less than 10 years. - Seriously ill individuals (people unable to engage in the normal activities of daily living without assistance because of their illnesses). |
Country | Name | City | State |
---|---|---|---|
Zambia | University of Zambia | Lusaka |
Lead Sponsor | Collaborator |
---|---|
Technical University of Munich |
Zambia,
Zulu G, Sikasunge CS, Welte TM, Simuunza MC, Stelzle D, Schmidt V, Hachangu A, Mutale W, Masuku M, Chembensofu M, da Costa CP, Mwape KE, Winkler AS, Phiri IK. Epidemiology of intestinal helminthiasis with an emphasis on taeniasis in Chipata district of th — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Prevalence of T. solium cysticercosis | Prevalence of human T. solium cysticercosis | Assessment through blood sampling at baseline | |
Primary | Prevalence of neurocysticercosis | Prevalence of human neurocysticercosis among people with positive serology for T. solium cysticercosis | Assessment at CT scanning at baseline | |
Primary | Prevalence of taeniosis | Prevalence of human T. solium taeniosis | Assessment through stool sampling at baseline | |
Secondary | Prevalence of intestinal helminth infection | Prevalence of intestinal helminth infection | Assessment through stool sampling at baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00527579 -
PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Neurocysticercosis Using [F-18]FB
|
Phase 1 | |
Completed |
NCT00526916 -
PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Neurocysticercosis Using [C-11]PBR28
|
Phase 1 | |
Terminated |
NCT02233855 -
People Presenting With Neurocysticercosis in North America
|
||
Recruiting |
NCT00001205 -
Natural History of Treated Neurocysticercosis and Long-Term Outcomes
|
||
Completed |
NCT02234570 -
Phase I Trial Evaluating the Safety and Pharmacokinetics of Oxfendazole
|
Phase 1 | |
Terminated |
NCT02947581 -
Sub Arachnoid Neurocysticercosis Treatment Outcome (SANTO)
|
Phase 3 | |
Completed |
NCT02243644 -
Effects of 2 Different Duration of Albendazole Therapy in Patients With Neurocysticercosis in Brain ≤ 5 Lesions on CT
|
Phase 3 | |
Not yet recruiting |
NCT06376396 -
Assessment of Combined Praziquantel and Albendazole vs Albendazole Alone to Treat Active Parenchymal Neurocysticercosis
|
Phase 4 | |
Completed |
NCT00441285 -
Neurocysticercosis: Combined Treatment With Praziquantel (PZQ) and Albendazole (ABZ)
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT04706819 -
Parenchymal and Extraparenchymal Neurocysticercosis-A Registry Based Study
|
||
Completed |
NCT00283699 -
A Pilot Study of Neurocysticercosis Treatment
|
Phase 3 | |
Terminated |
NCT02945527 -
Treatment of Peri-calcification Edema in Neurocysticercosis (NCC)
|
Phase 2/Phase 3 | |
Completed |
NCT00290823 -
Corticosteroids to Reduce Frequency of Seizures in Neurocysticercosis Patients
|
Phase 3 | |
Completed |
NCT03834337 -
Treatment of Patients With Active Neurocysticercosis in Eastern Africa
|
||
Completed |
NCT03851419 -
The Burden of (Neuro)Cysticercosis Among People Living With HIV in Rural Tanzania
|